drugset / Trial / NCT00437437

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

NCT00437437

Phase 1 Completed 29 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate

Timeline

Start
2000-05
Primary completion
2008-05
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivanib Small molecule 800 mg Oral

Indications